| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Adventitious agents, new technology, and risk assessment, 19–20 May 2011, Baltimore, MD
|
Sheets, Rebecca
|
|
2012
|
40 |
2 |
p. 162-167
6 p.
|
article
|
| 2 |
Aims and Scope/Editorial Board/Publishing Details
|
|
|
2012
|
40 |
2 |
p. IFC-
1 p.
|
article
|
| 3 |
Application of a risk analysis method to different technologies for producing a monoclonal antibody employed in Hepatitis B vaccine manufacturing
|
Milá, Lorely
|
|
2012
|
40 |
2 |
p. 118-128
11 p.
|
article
|
| 4 |
Development and calibration of a standard for the protein content of granulocyte colony-stimulating factor products
|
Gao, Kai
|
|
2012
|
40 |
2 |
p. 151-157
7 p.
|
article
|
| 5 |
Development and qualification of an antibody rapid deglycosylation method
|
Cook, K. Steven
|
|
2012
|
40 |
2 |
p. 109-117
9 p.
|
article
|
| 6 |
Development and validation of an egg-based potency assay for a trivalent live attenuated influenza vaccine
|
Yeolekar, Leena R.
|
|
2012
|
40 |
2 |
p. 146-150
5 p.
|
article
|
| 7 |
Efficacy evaluation of live Escherichia coli expression Brucella P39 protein combined with CpG oligodeoxynucleotides vaccine against Brucella melitensis 16M, in BALB/c mice
|
Al-Mariri, Ayman
|
|
2012
|
40 |
2 |
p. 140-145
6 p.
|
article
|
| 8 |
International workshop
|
|
|
2012
|
40 |
2 |
p. 168-
1 p.
|
article
|
| 9 |
Low pH formulation of whole IgG antivenom: Impact on quality, safety, neutralizing potency and viral inactivation
|
Solano, Silvia
|
|
2012
|
40 |
2 |
p. 129-133
5 p.
|
article
|
| 10 |
Safety and immunogenicity of a monovalent MF59®-adjuvanted A/H1N1 vaccine in HIV-infected children and young adults
|
Palma, Paolo
|
|
2012
|
40 |
2 |
p. 134-139
6 p.
|
article
|
| 11 |
Serological profile of buffalo (Bubalus bubalis) female calves vaccinated with standard Brucella abortus strain 19 vaccine using rose bengal, 2-mercaptoethanol and complement fixation tests
|
Nardi Júnior, G.
|
|
2012
|
40 |
2 |
p. 158-161
4 p.
|
article
|
Journal description